Brain Tumours-remaining an area of unmet need

The Challenge of Brain Tumours

Brain tumours can originate within the brain (primary) or spread from other parts of the body (metastatic). Malignant tumours, such as glioblastomas, are particularly aggressive, while benign tumours, although non-cancerous, can still be life-threatening due to their impact on brain function. Diagnosing brain tumours is challenging due to symptom overlap with other neurological conditions. Although imaging technologies have advanced, early and precise detection remains difficult. Treatments—including surgery, radiation, and chemotherapy—are often limited by tumour location, resistance to therapy, and the need to preserve healthy brain tissue.

Key Statistics:

• Over 300,000 new cases of brain and central nervous system (CNS) tumours are diagnosed annually worldwide.
• Glioblastoma has a median survival rate of only 12–15 months.

The Need for Continued Research

Brain tumour research is a critical medical and humanitarian effort. Progress requires collaboration across disciplines—neuroscience, oncology, genomics, and data science. Continued scientific innovation, collaborative research, and strategic investment are key to improving survival rates and quality of life for those affected.

Ongoing research is focused on:

• Biomarker discovery for earlier and more accurate diagnosis
• Develop tumour cell targeted therapies
• Understanding molecular and genetic drivers of tumour growth.
• Create effective drug delivery systems that bypass the blood-brain barrier.

Market Growth and Investment Trends

The brain cancer treatment market is experiencing robust growth, driven by advancements in targeted therapies, immunotherapies, and personalised medicine. Valued at approximately USD 1.9 billion in 2023, the global brain tumour therapeutics market is projected to reach USD 4.2 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.5%.

• In the United States, the market is expected to grow from USD 1.25 billion in 2024 to USD 1.87 billion by 2030, at a CAGR of 7.2%. This expansion is fuelled by increased regulatory approvals, such as the FDA’s 2024 approval of a new drug for low-grade diffuse gliomas—the first in over two decades.
• The European brain tumour treatment market is projected to grow from approximately USD 960 million in 2022 to USD 1.9 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.9%. This growth is fuelled by factors such as an aging population, increased incidence of high-grade gliomas, and substantial investments in cancer research and healthcare infrastructure across countries like Germany, France, and the UK. Business Market Insights
• In the APAC region, the brain tumour diagnosis and therapeutics market generated revenue of USD 749.0 million in 2024 and is expected to reach USD 1.2 billion by 2030, growing at a CAGR of 8.7%. This expansion is attributed to rapid advancements in healthcare infrastructure, increasing investments in medical research, and a growing prevalence of brain tumours in countries such as China, India, and Japan.